Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK006 in Breast Cancer-related Bone Metastases
NCT03487055Phase 1Unknown
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of TK006 in bone metastasis, sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Incidence of adverse events related to TK006 treatment at 85 days. Status: unknown.
02
Drugs
TK006
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT03487055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487055.